Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

NCT03299686 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: CJM112
OTHER: Placebo to CJM112

Sponsor

Novartis Pharmaceuticals